Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026, reporting net sales of DKK 78.488 billion (approximately USD 12.1 billion), representing a 7% year-over-year increase at constant exchange rates (CER). For the first half of 2026, net sales reached DKK 148.551 billion (approximately USD 22.9 billion), up 2% year-over-year.
Financial Performance Snapshot
| Metric | Q2 2026 | YoY Change (CER) | H1 2026 | YoY Change (CER) |
|---|---|---|---|---|
| Net Sales | DKK 78.488B | +7% | DKK 148.551B | +2% |
| US Market | DKK 40.869B | +4% | DKK 76.254B | -4% |
| Europe & Canada | DKK 19.206B | +17% | DKK 37.124B | +8% |
| Emerging Markets | DKK 8.413B | +5% | DKK 15.274B | -7% |
| Asia-Pacific | DKK 5.03B | -6% | DKK 10.155B | +7% |
| China Market | DKK 4.97B | +13% | DKK 9.744B | Flat |
Therapeutic Segment Performance
Obesity Care
- Total Q2 Sales: DKK 23.152B (+16% YoY)
- Wegovy (semaglutide injection for weight management): DKK 19.484B (+1% YoY)
- Tablet Sales: DKK 3.218B (not specified individually)
GLP-1 Diabetes Care
- Total Q2 Revenue: DKK 36.784B (+2% YoY)
- Ozempic (semaglutide injection for diabetes): DKK 31.375B (+5% YoY)
- Combined Wegovy Tablets & Rybelsus: DKK 5.228B (-4% YoY)
Geographic Market Analysis
- US Market: Remains the largest revenue contributor with DKK 40.869B in Q2, showing modest 4% growth despite H1 decline of 4%
- Europe & Canada: Strongest regional performer with 17% Q2 growth, driven by robust semaglutide adoption
- China Market: Notable 13% Q2 growth demonstrates continued expansion in the world’s second-largest pharmaceutical market
- Asia-Pacific: Experienced 6% Q2 decline, offset by 7% H1 growth, indicating regional volatility
Pipeline Restructuring Decision
Novo Nordisk announced the termination of monlunabant development, an experimental compound targeting the cannabinoid receptor 1 (CB1 receptor) acquired through the $1.1 billion acquisition of Canadian biotech firm Inversago Pharma in 2023.
Reasons for Termination:
- Limited efficacy: Higher doses yielded insufficient weight loss benefits
- Safety concerns: Mild-to-moderate neuropsychiatric side effects observed in clinical trials
- Portfolio optimization: Strategic reallocation of resources to higher-potential candidates
This decision reflects Novo Nordisk’s disciplined approach to pipeline management, prioritizing compounds with superior risk-benefit profiles and commercial potential.
Market Outlook & Strategic Focus
- Semaglutide Dominance: Continued strong performance across both obesity and diabetes indications validates the company’s core therapeutic focus
- Geographic Diversification: Robust growth in Europe and China partially offsets US market challenges
- Pipeline Prioritization: Resource reallocation from terminated programs to advance high-value candidates
- Innovation Investment: Ongoing commitment to next-generation obesity and diabetes therapeutics
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, pipeline development, and strategic decisions. Actual results may differ due to risks including regulatory approvals, competitive dynamics, market access, and clinical trial outcomes.-Fineline Info & Tech
